Comprehensive characterization of the tumor microenvironment for assessing immunotherapy outcome in patients with head and neck squamous cell carcinoma

被引:0
|
作者
Zhang, Jian [1 ,2 ]
Zhong, Xi [3 ]
Jiang, Huali [4 ]
Jiang, Hualong [5 ]
Xie, Tao [1 ,2 ]
Tian, Yunhong [1 ,2 ]
Li, Rong [1 ,2 ]
Wang, Baiyao [1 ,2 ]
Zhang, Jiexia [6 ]
Yuan, Yawei [1 ,2 ]
机构
[1] Guangzhou Med Univ, Affiliated Canc Hosp & Inst, Dept Radiat Oncol, Guangzhou 510095, Peoples R China
[2] Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou 510095, Peoples R China
[3] Guangzhou Med Univ, Radiat Dept, Affiliated Canc Hosp & Inst, Guangzhou 510095, Peoples R China
[4] Sun Yat Sen Univ, Dept Cardiovascularol, Tungwah Hosp, Dongguan 523000, Peoples R China
[5] Sun Yat Sen Univ, Dept Urol, Tungwah Hosp, Dongguan 523000, Peoples R China
[6] Guangzhou Med Univ, State Key Lab Resp Dis, Natl Clin Res Ctr Resp Dis, Guangzhou Inst Resp Hlth,Affiliated Hosp 1, Guangzhou 510120, Peoples R China
来源
AGING-US | 2020年 / 12卷 / 22期
关键词
head and neck squamous cell carcinoma; tumor microenvironment; immunotherapy; single nucleotide variants; copy number variations; PD-1; BLOCKADE; MUTATIONAL PROCESSES; BREAST-CANCER; COPY-NUMBER; EXPRESSION; RECURRENT; PEMBROLIZUMAB; LANDSCAPE; NIVOLUMAB; SIGNATURES;
D O I
暂无
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The tumor microenvironment (TME) constitutes a complex milieu of cells and cytokines that maintain equilibrium between tumor progression and prognosis. However, comprehensive analysis of the TME and its clinical significance in head and neck squamous cell carcinoma (HNSCC) remains to be unreported. In this study, based on large-scale RNA sequencing data pertaining to single nucleotide variants (SNVs) and copy number variations (CNVs) in HNSCC patients from The Cancer Genome Atlas database, we analysed subpopulations of infiltrating immune cells and evaluated the role of TME infiltration pattern (TME score) in assessing immunotherapy outcome. TME signature genes involved in several inflammation and immunity signalling pathways were observed in the TME score subtype, which were considered immunosuppressive and potentially responsible for significantly worse prognosis. In comparison with SNVand CNV-mediated tumor mutation burden, TME score can significantly differentiate between highand low-risk HNSCC and predict immunotherapy outcome. Our data provide clarity on the comprehensive landscape of interactions between clinical characteristics of HNSCC and tumor-infiltrating immune cells. TME score seems to be a useful biomarker that can predict immunotherapy outcome in HNSCC patients.
引用
收藏
页码:22509 / 22526
页数:18
相关论文
共 50 条
  • [31] Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma
    Kwon, Minsu
    Lee, Yoon Se
    Jung, Hanul
    Kim, Min Ji
    Kang, So Hee
    Seo, Ji-Hyun
    Park, Jung Je
    CLINICAL CANCER RESEARCH, 2023, 29 (18)
  • [32] Statin in combination with cisplatin makes favorable tumor-immune microenvironment for immunotherapy of head and neck squamous cell carcinoma
    Minsu, K.
    Jung, H.
    Cho, H. J.
    Ahn, H. R.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S123 - S123
  • [33] The Tumor Microenvironment and Immunotherapy of Oropharyngeal Squamous Cell Carcinoma
    Welters, Marij J. P.
    Santegoets, Saskia J.
    van der Burg, Sjoerd H.
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [34] Highly Multiplexed Digital Spatial Profiling of the Tumor Microenvironment of Head and Neck Squamous Cell Carcinoma Patients
    Kulasinghe, Arutha
    Taheri, Touraj
    O'Byrne, Ken
    Hughes, Brett G. M.
    Kenny, Liz
    Punyadeera, Chamindie
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [35] The promise of immunotherapy in head and neck squamous cell carcinoma
    Economopoulou, P.
    Agelaki, S.
    Perisanidis, C.
    Giotakis, E. I.
    Psyrri, A.
    ANNALS OF ONCOLOGY, 2016, 27 (09) : 1675 - 1685
  • [36] Immunotherapy in the management of squamous cell carcinoma of the head and neck
    Subramaniam, S. S.
    Paterson, C.
    McCaul, J. A.
    BRITISH JOURNAL OF ORAL & MAXILLOFACIAL SURGERY, 2019, 57 (10): : 957 - 966
  • [37] Neoadjuvant immunotherapy for head and neck squamous cell carcinoma
    Kuerten, Cornelius H. L.
    Ferris, Robert L.
    LARYNGO-RHINO-OTOLOGIE, 2024, 103 : S167 - S187
  • [38] Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma
    Almokadem, Salah
    CURRENT MOLECULAR PHARMACOLOGY, 2016, 9 (03) : 226 - 230
  • [39] The characterization of tumor immune microenvironment after neoadjuvant immunotherapy in head and neck squamous cell cancer using multiplex immunohistochemistry
    An, Zhaohong
    Zhang, Xiwei
    Wang, Zhaoyang
    Wusiman, Dilinaer
    Zhao, Xiaohui
    Li, Lin
    Guo, Lei
    Wei, Minghui
    Li, Wenbin
    An, Changming
    ORAL ONCOLOGY, 2025, 161
  • [40] Tumor Histological Grade and Immunotherapy Response in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
    Alkhatib, Hosam H.
    Maroun, Christopher A.
    Amin, Neha
    Zhu, Gangcai
    Guller, Meytal
    Herberg, Matthew E.
    Wu, Evan S.
    Seiwert, Tanguy Y.
    Rooper, Lisa M.
    Eisele, David W.
    Fakhry, Carole
    Pardoll, Drew
    Mandal, Rajarsi
    JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2022, 148 (06) : 540 - 546